Albumin-proaerolysin prodrugs
AssigneeThe Johns Hopkins University
InventorsJohn T. Isaacs, Samuel R. Denmeade, Nathaniel E. Brennen
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.
Claims15
A prodrug composition comprising:
- a. a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA;
- and
- b. human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.
A recombinant protein comprises SEQ ID NO:48.
A prodrug composition comprising:
- a. a prostate-specific protease-activated pro-aerolysin (PA), wherein a prostate-specific protease cleavable linker replaces the native furin cleavage site within PA;
- and
- b. a blood plasma protein or a fragment thereof fused to the N-terminus of the PSA-activated PA.
Dependencies are inferred from the claim text.